Empagliflozin
02:52
PTPHF||What do we know about the consistency of the results for empagliflozin across the spectrum of ejection fraction?
02:27
PTPHF||What is the impact on the treatment landscape from the early benefits seen in the EMPEROR trials?
05:42
PTPHF||What is the impact of SGLT-2i trials in HFpEF?
04:22
PTPHF||How has the HFpEF guidelines evolved with the advent of SGLT2i trials?
04:25
PTPHF||Guidelines recommend the 4-pillar approach in managing HFrEF. What is a practical approach to implement this?
PDF